Jeff Gerth was a senior reporter at ProPublica. Previously, he worked as an investigative reporter at The New York Times from 1976 through 2005. His work has twice been honored with the Pulitzer Prize. He also won a George Polk Award. His often-prescient coverage has run the gamut from Al Qaeda to Enron, from Whitewater to Chinese technology transfers. During 2004 he was a visiting professor at Princeton University, where he taught an undergraduate seminar on investigative reporting. Gerth is also the co-author (with Don Van Natta Jr.), of Her Way: The Hopes and Ambitions of Hillary Rodham Clinton, published in 2007.
The SEC wants to know whether GE was sending conflicting signals about its financial situation in 2008. Investors got no indication of trouble, but Hank Paulson says he was alarmed by information he got from Jeff Immelt, the company's CEO.
GE Healthcare ignored the advice of its own safety experts to “proactively” restrict the use of its imaging drug, Omniscan, after reports in Europe linked the drug to a potentially crippling disease, according to a newly unsealed order in a lawsuit against the company.
Recent reports and testimony suggest that a crucial ingredient is in short supply in financial regulation: cooperation among the watchdogs. The collapse of Lehman Brothers presents a case in point.
A 2005 report by other Federal Reserve banks found that the New York Fed did not have the resources to supervise Citigroup. But Alan Greenspan, who was the Fed chairman at the time, says that Timothy Geithner never called to ask for more.
GE Healthcare and a Danish radiologist have settled a British libel suit in which GE claimed that the radiologist had made damaging statements about GE's MRI imaging drug Omniscan. The suit had raised questions about whether British libel laws were so strict they impede free speech.
In private conversations that alarmed then-Treasury Secretary Henry Paulson, Immelt laid out a different picture of GE’s credit situation, according to Paulson’s new book about the crisis
GE is suing a radiologist for defamation in England, citing his descriptions of adverse reactions to GE's MRI drug Omniscan, which has been linked to serious injuries to patients with kidney disease. The suit is fueling a debate over British libel laws, which have been seen as draconian toscientists.
After a daylong hearing, an FDA advisory panel recommends effectively banning the use of GE’s Omniscan and Covidien’s Optimark in patients with severe kidney disease. The MRI contrast agents have been linked to a rare but often crippling disease, nephrogenic systemic fibrosis.
GE's imaging drug Omniscan and two other similar MRI drugs may face stiffer regulation after an FDA study indicates they might be riskier for patients with kidney disease.